HHHatice Canan Hasanoğlu

Hatice Canan Hasanoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hatice Canan Hasanoğlu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ischemia-modified albumin as a marker of disease severity and hospitalization in community-acquired pneumonia: a prospective case–control study

    by Melis Yağdıran, Ebru Şengül Parlak, Hatice Canan Hasanoğlu, Özcan Erel

    Aims: Community-acquired pneumonia (CAP) is an important public health problem because of its high morbidity, mortality, and health care costs. Many biomarkers have been used to determine the severity and prognosis of pneumonia. Ischemia-modified albumin (IMA) is a marker of the recently used oxidant-antioxidant mechanism and has been found to increase in many inflammatory conditions. Objectives: To investigate the role of the levels of IMA in CAP and to evaluate its relationship with pneumonia severity. Methods: A total of 150 patients with a diagnosis of CAP and 150 healthy individuals were included in the study. IMA levels were evaluated in both groups. The patients with CAP were divided into ambulatory, ward and intensive care groups, and their IMA levels were compared. Results: There was no significant difference between the two groups in terms of age or gender (p>0.05 for both). No significant difference was observed in the IMA levels of the patient and control groups (p>0.05). The lowest IMA level was observed in the ambulatory group (p=0.001). When the patients in the ambulatory and hospitalized (ward and intensive care together) groups were evaluated, the cut-off value of IMA was 77.60 ABSU, sensitivity was 64.9%, specificity was 75.0%, positive predictive value was 89.2%, and negative predictive value was 40.3%. Conclusion: In the management of patients with CAP, IMA seems to be a useful marker for CAP severity and hospitalization decision.

  • Open Access

    Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?

    by Hatice Kiliç, Emine Argüder, Musa Ci̇vAk, Emin Gemci̇oĞlu, Ayşe KAYA KALEM, İmRan Hasanoğlu, Bircan Kayaaslan, Sibel Günay, Esmehan Akpinar, Habibe Hezer, et al.

    It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.


  • Open Access

    Evaluation of Upper Extremity Venous Thrombosis with Doppler Ultrasonography in Peripheral Venous Line Applied Patients

    by Habibe Hezer, Hatice Kiliç, Sevim Öğülmüş, Funda Karaduman Yalçin, Hatice Canan Hasanoğlu

    Objectives: Peripherally inserted venous lines (PVL) may increase the risk of venous thrombosis due to vessel wall disarrangement. Aim of this study is to identify the cases of upper extremity venous thrombosis (UEVT) related to PVL since most of the PVLs applied to upper extremities. Methods: Sixty-nine hospitalized patients with previous or present PVL insertions were included in this prospective study. Upper extremity Doppler compression ultrasonography (USG) examination were performed to on all patients. The cases with detected UEVTs were evaluated as group 1 and the remaining cases were evaluated as group 2. Demographic parameters, PVL applications, intravenous treatments were compared between the groups. Results: UEVT was diagnosed by Doppler USG in 26 (37.7%) patients out of 69 patients. Lower extremity thrombosis was found in 10 (14.49%) patients. UEVT was observed in cephalic vein in 14 (53.8%) and in basilic vein in four (15.4%) out of 26 (37.7%) patients. Axillary and brachial deep UEVT was located in two (2.9%) cases. Superficial UEVT was found in 24 (34.8%) cases. Ceftriaxone, cefoperazone/sulbactam and esomeprazole were the mostly associated treatments with UEVT. UEVT was detected in five patients with PVL that were inserted only for drawing blood. Conclusion: PVL is a risk factor for UEVT since almost 1/3 of the patients revealed UEVT. When PVL is no longer needed or the need for intravenous therapy decreases, oral therapy should be planned and PVL should be removed. Removal of PVL appears to be necessary to avoid UEVT.

  • Comparison of clinical and radiological characteristics of COVID-19 patients with and without pneumothorax and/or pneumediastinum

    by Emine Argüder, Meltem Fidan, Halil Tekdemir, Bökebatur Ahmet Raşit Mendi, Abdullah Fidan, Hayriye Cankar Dal, Ümran Özden Sertçelik, İrEm Şerifoğlu, Sibel Günay, Dilek Kazancı, et al.

    Pneumothorax (PTX) and pneumomediastinum (PM) are frequently encountered in patients with Coronavirus disease 2019 (COVID-19) and complicate the management of these patients. In this study, we aimed to evaluate the risk factors that cause PTX/PM complications in patients hospitalized due to COVID-19 pneumonia and the effects of these complications on the course of the disease. A total of 503 patients with COVID-19 hospitalized in the COVID-19 ward or intensive care unit (ICU) between September 2020 and December 2020 were included in the study. The median age of patients was 65 (min-max, 21-99) years. Of the patients 299 (59.4%) were male and 204 (40.6%) were female. Of the cases, 26 (5.2%) developed PTX or PM. The patients who developed PTX/PM were older than patients who did not [58.5 (min-max, 21-96) vs 65 years (min-max, 22-99), p= 0.029]. The percentage of PTX/PM development was significantly higher in male patients [F/M= 4/22 (2/7.4%) vs 200/277 (98/92.6%), p= 0.007]. Hypertension as a comorbidity was more commonly seen in the group without PTX/PM (p= 0.007). Ground-glass opacity was the most common tomographic finding in both groups, it was significantly higher in those who did not develop PTX/PM (p<0.001). The length of hospital stay was shorter in patients with PTX/PM (p<0.001), but mortality was higher (p= 0.04). PTX/PM were relatively more common in COVID-19 patients. These complications may negatively affect the prognosis of the disease.


  • The Role of Pneumococcal Pneumonia among Community-Acquired Pneumonia in Adult Turkish Population: TurkCAP Study

    by Esin Senol, Aykut Cilli, Hakan Gunen, Alper Sener, Ridvan Dumlu, Ayse Odemis, Ayse Fusun Topcu, Yesim Yildiz, Rahmet Guner, Ayhan Ozhasenekler, et al.

    Streptococcus pneumoniae,community-acquired pneumonia,adult


  • Behcet’s disease presenting with pulmonary thromboembolism

    by Seray Abuzaina, Sevil Pempeci, Emine Argüder, Ayşegül Karalezli, H. Canan Hasanoğlu


  • Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism

    by Hatice Kilic, H.CAnan Hasanoglu, Aysegul Karalezli, Habibe Hezer, Elif Babaoglu, Mukremin Er, E. Sengül Parlak, Osama Abuzaina, Derya Oztuna, Emine Arguder

    Purpose: The treatment of Pulmonary Embolism (PE) which is life threatening disease must be planned considering risk – benefit relationship. In this study, patients with PE given thrombolytic therapy, low-molecular-weight heparin and warfarin were monitored for 5 years to compare them in terms of hemorrhage side effect due to therapy. Method: A total of 219 patients were included in the study. 50.2% (n=109) of the patient’s were female and 49.8% (n=110) were male, (p=0.20). Clinical findings, radiologic and laboratory parameters were recorded retrospectively. A total of 121 (55.25%) patients were given thrombolytic therapy (Group 1 n=121). Enoxaparin therapy was given to 205 patients (Group 2). During therapy maintenance, warfarin therapy conducted for 159 patients (Group 3). Results: Cerebral hemorrhage observed in 1 case (0.83%) in group 1, 2 case (0.98%) in group 2 and 1 case (0.62%) in group 3 (p>0.05). Gastrointestinal system (GI) bleeding happened 2 cases (1.65%) in group 1 and 2 cases (0.98%) in group 2 (p>0.05). Minor bleeding was observed at similar rates due to the treatments. There was no fatality due to hemorrhage. There is no significant difference in terms of death, recurrence, residuel chronic thrombus and chronic PE in the follow up for five years between rt-PA group (group1) and non rt-PA group (p>0.05). Conclusion: According to our results; major hemorrhage observed similar in thrombolytic, enoxaparin and warfarin therapy. Study results about the rate of cerebral hemorrhage related to thrombolytic therapy was low in contrast to the results reported in some literature before.


  • The Geographical Distribution of Morbidity Caused By Chronic Obstructive Pulmonary Disease in Turkey: COPDTURKEY-2

    by Mustafa Hamidullah Türkkanı, Tarkan Özdemir, Hatice Kılıç, Nilgün Yılmaz Demirci, Çiğdem Özdilekcan, H. Canan Hasanoğlu, Orhan Koç, Can Öztürk

    Background: Chronic obstructive pulmonary disease (COPD) is one of the most prevalent causes for morbidity and mortality, and it creates a cumulative economic and social burden. Aims: To determine the distribution of the prevalence of patients in Turkey who were diagnosed with COPD and their morbidity rates, according to the regions and cities they belong to. Moreover, the study contributes to the prevention and cure services of COPD that should be planned in the future. Study Design: A retrospective cohort. Methods: The database of the Social Security Institution from 2016 has been scanned. All the data with prescription registration, with the code ICD-10, J44.0-J44.9, which were aimed for diagnosing and/or cure, have been evaluated with a retrospective cohort. Results: In 2016, 955,369 patients who were admitted as outpatients to the hospitals were diagnosed with COPD. The average number of annual COPD cases that were admitted was 2.09. Twenty percent (20%) of the outpatient applications were via emergency room. The rate of hospitalization among the applicants was 17.75%. with a total of 1,994,325. The average annual number of hospitalizations of men was higher than that of women. The average number of hospitalization days was 6.52. The region with the highest prevalence of outpatient admission and hospitalization was the Black Sea Region. Conclusion: The high rate of hospitalization was considered to be the outcome of the insufficient "outpatient" management.


  • Thiol‐disulfide as a novel indicator of obstructive sleep apnea

    by Emine Argüder, Ebru Şengül Parlak, Hatice Kılıç, Habibe Hezer, Salim Neşelioğlu, Hatice Canan Hasanoğlu, Gökhan Yalçıner, Mehmet Ali Babademez, Özcan Erel

    Introduction: Obstructive sleep apnea (OSA) is an oxidative stress disease, which has been considered to be a notable risk and associated with increased cardiovascular morbidity and mortality. Thiol‐disulfide homeostasis is as a novel indicator of oxidative stress.Objectives: We aimed to evaluate thiol‐disulfide homeostasis in a large patient population with OSA.Methods: A total of 230 with OSA and 40 healthy controls were included in the study. Inclusion criteria for OSA patients are having apnoea‐hypopnoea index of ≥5/hour, being more than 18 years of age and having no previous treatment for OSA. Thiol‐disulfide analysis was done for the patients and control group. Blood thiol‐disulfide homeostasis was analysed using the new automatic method, developed by Erel and Neşelioğlu.Results: Among all OSA subjects, 149 (64.8%) were males and the mean ages of the patients were 53.38 ± 10.22. Total thiol, native thiol (SH) and disulfide (SS) levels were significantly lower in OSA group compared to the control group (P < .001, P < .001 and P = .039 respectively). Also, total thiol and native thiol (SH) were significantly different between the groups according to OSA severity (mild‐moderate to severe OSA) (P < .001 and P < .001 respectively). Thiol‐disulfide redox parameters were correlated with apnoea‐hypopnoea index (AHI) scores.Conclusion: The present prospective study showed that thiol/disulfide homeostasis was unbalanced in OSA patients. Especially, in OSA patients have low level of thiol/disulfide redox parameters when compared to healthy subjects. Evaluating thiol‐disulfide homeostasis in OSA may be a contributing aspect to assessment and monitoring of the patient.